Age-adjusted Pearson's correlation between A-FABP and chemerin with metabolic parameters.

<p>*<i>p</i><0.05; hs-CRP, high-sensitivity C-reactive protein; A-FABP, adipocyte fatty acid-binding protein.</p

Crude incidence rates of outcomes.

<p>Crude incidence rates of outcomes.</p

Baseline characteristics.

<p>Baseline characteristics.</p

Baseline characteristics, abdominal fat areas, and myocardial perfusion imaging.

<p>SD, standard deviation; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; A-FABP, adipocyte fatty acid-binding protein; LVEF, left ventricular ejection fraction; SSS, summed stress score; SDS, summed difference score.</p

Relative risk of cancer incidence by modeling the cumulative incidence while considering the competing risk of death (Fine and Gray’s subdistribution method).

<p>Relative risk of cancer incidence by modeling the cumulative incidence while considering the competing risk of death (Fine and Gray’s subdistribution method).</p

Diagram of patient flow.

<p>Diagram of patient flow.</p

Predictive ability of A-FABP and chemerin for significant ischemia.

<p>Model 0: no adjustment.</p><p>Model 1: adjusted for age.</p><p>Model 2: adjusted for age, systolic blood pressure.</p><p>Model 3: adjusted for age, systolic blood pressure, history of coronary artery disease.</p><p>A-FABP, adipocyte fatty acid-binding protein.</p

Associations of clinical characteristics and biomarkers with increased stress lung-to-heart ratio during myocardial perfusion imaging.

<p>HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; A-FABP, adipocyte fatty acid-binding protein.</p

The standardized incidence ratio.

<p>The standardized incidence ratio and 95% confidence interval of all cancers and different types of cancer compared with the general population. Numbers shown are observed number of cancer cases/expected number of cancer cases.</p

Predictive ability of A-FABP and chemerin for metabolic syndrome.

<p>Model 0: no adjustment.</p><p>Model 1: adjusted for age.</p><p>Model 2: adjusted for age, body mass index.</p><p>Model 3: adjusted for age, visceral adipose tissue area.</p><p>A-FABP, adipocyte fatty acid-binding protein.</p